+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 92 Pages
  • October 2023
  • Region: Global
  • Grand View Research
  • ID: 5899559
Description Jump to:
The global liver cancer drug market size is expected to reach USD 7.83 billion by 2030, registering a CAGR of 15.3% during the forecast period. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights

  • The North America accounted for more than 43.20% of the market in 2022. Multiple product launches, increasing adoption of novel therapeutics, and presence of a large target population are contributing to the growth of the market in the region
  • Approval of multiple novel drugs in recent years is one of the key factors augmenting the liver cancer treatment market. New immuno-oncology products and combination therapies are anticipated to change the landscape over the next years.
  • Combination regimens, specifically those including checkpoint inhibitors, will be introduced in the first-line setting to target major unmet needs, including overcoming tumour resistance, improving progression free survival, and maintaining quality of life
  • The liver cancer market pipeline is highly innovative and diverse. The market offers tremendous opportunities to develop breakthrough first-in-class therapies due to high unmet needs. In recent years, innovative treatment approaches such as oncolytic viruses or RNA interference (RNAi) technology have gained significant traction in the market.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Drug Class
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Liver Cancer Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Liver Cancer Drugs Market Analysis Tools
3.4.1. Industry Analysis - Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Liver Cancer Drugs Market: Drug Class Estimates & Trend Analysis
4.1. Liver Cancer Drugs Market: Key Takeaways
4.2. Liver Cancer Drugs Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
4.3. Targeted Therapy
4.3.1. Targeted therapy market estimates and forecasts, 2018 to 2030, (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030, (USD Million)
4.5. Chemotherapy
4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030, (USD Million)
Chapter 5. Liver Cancer Drugs Market: Regional Estimates & Trend Analysis
5.1. Regional Outlook
5.2. Liver Cancer Drugs Market by Region: Key Takeaways
5.3. North America
5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.3.2. U.S.
5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.3.3. Canada
5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.2. Germany
5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.3. France
5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.4. Italy
5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.5. Spain
5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.6. Denmark
5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.7. Sweden
5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.4.8. Norway
5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.2. China
5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.3. India
5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.4. Australia
5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.5. Thailand
5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.5.6. South Korea
5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6.2. Mexico
5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.6.3. Argentina
5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7. MEA
5.7.1. South Africa
5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.2. Saudi Arabia
5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.3. UAE
5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
5.7.4. Kuwait
5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Market Participant Categorization
6.2.1. Bayer AG
6.2.1.1. Company overview
6.2.1.2. Financial performance
6.2.1.3. Product benchmarking
6.2.1.4. Strategic initiatives
6.2.2. Bristol-Myers Squibb Company
6.2.2.1. Company overview
6.2.2.2. Financial performance
6.2.2.3. Product benchmarking
6.2.2.4. Strategic initiatives
6.2.3. Eisai Co., Ltd.
6.2.3.1. Company overview
6.2.3.2. Financial performance
6.2.3.3. Product benchmarking
6.2.3.4. Strategic initiatives
6.2.4. Exelixis, Inc.
6.2.4.1. Company overview
6.2.4.2. Financial performance
6.2.4.3. Product benchmarking
6.2.4.4. Strategic initiatives
6.2.5. Merck KGaA
6.2.5.1. Company overview
6.2.5.2. Financial performance
6.2.5.3. Product benchmarking
6.2.5.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 3 North America liver cancer drugs market, by region, 2018-2030 (USD Million)
Table 4 U.S. liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 5 Canada liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 6 Europe liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 7 Europe liver cancer drugs market, by region, 2018-2030 (USD Million)
Table 8 Germany liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 9 UK liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 10 France liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 11 Italy liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 12 Spain liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 13 Denmark liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 14 Sweden liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 15 Norway liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 16 Asia Pacific liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 17 Asia Pacific liver cancer drugs market, by region, 2018-2030 (USD Million)
Table 18 China liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 19 Japan liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 20 India liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 21 Australia liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 22 Thailand liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 23 South Korea liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 24 Latin America liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 25 Latin America liver cancer drugs market, by region, 2018-2030 (USD Million)
Table 26 Brazil liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 27 Mexico liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 28 Argentina liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 29 Middle East and Africa liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 30 Middle East and Africa liver cancer drugs market, by region, 2018-2030 (USD Million)
Table 31 South Africa liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 32 Saudi Arabia liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 33 UAE liver cancer drugs market, by drug class, 2018-2030 (USD Million)
Table 34 Kuwait liver cancer drugs market, by drug class, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Liver cancer drugs: Market outlook
Fig. 8 Liver cancer drugs: Competitive insights
Fig. 9 Parent market outlook
Fig. 10 Related/ancillary market outlook
Fig. 11 Penetration and growth prospect mapping
Fig. 12 Liver cancer drugs market driver impact
Fig. 13 Liver cancer drugs market restraint impact
Fig. 14 Liver cancer drugs market strategic initiatives analysis
Fig. 15 Liver cancer drugs market: Drug class movement analysis
Fig. 16 Liver cancer drugs market: Drug class outlook and key takeaways
Fig. 17 Targeted therapy market estimates and forecasts, 2018-2030 (USD Million)
Fig. 18 Immunotherapy market estimates and forecasts, 2018-2030 (USD Million)
Fig. 19 Chemotherapy market estimates and forecasts, 2018-2030 (USD Million)
Fig. 20 Global liver cancer drugs market: Regional movement analysis
Fig. 21 Global liver cancer drugs market: Regional outlook and key takeaways
Fig. 22 North America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 23 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Fig. 24 Canada market estimates and forecasts, 2018-2030 (USD Million)
Fig. 25 Europe market estimates and forecasts, 2018-2030 (USD Million)
Fig. 26 UK market estimates and forecasts, 2018-2030 (USD Million)
Fig. 27 Germany market estimates and forecasts, 2018-2030 (USD Million)
Fig. 28 France market estimates and forecasts, 2018-2030 (USD Million)
Fig. 29 Italy market estimates and forecasts, 2018-2030 (USD Million)
Fig. 30 Spain market estimates and forecasts, 2018-2030 (USD Million)
Fig. 31 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Fig. 32 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Fig. 33 Norway market estimates and forecasts, 2018-2030 (USD Million)
Fig. 34 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Fig. 35 Japan market estimates and forecasts, 2018-2030 (USD Million)
Fig. 36 China market estimates and forecasts, 2018-2030 (USD Million)
Fig. 37 India market estimates and forecasts, 2018-2030 (USD Million)
Fig. 38 Australia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 39 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Fig. 40 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Fig. 41 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 42 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Fig. 43 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Fig. 44 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Fig. 45 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Fig. 46 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Fig. 47 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 48 UAE market estimates and forecasts, 2018-2030 (USD Million)
Fig. 49 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Merck KGaA

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages92
PublishedOctober 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 2.44 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.83 Billion
Compound Annual Growth Rate15.3%
Regions CoveredGlobal
No. of Companies Mentioned5

Related Topics

Related Reports

Global Liver Cancer Drugs Market by Type (Immuno Therapy, Targeted Therapy), Distribution channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Forecast 2024-2030 - Product Image

Global Liver Cancer Drugs Market by Type (Immuno Therapy, Targeted Therapy), Distribution channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Forecast 2024-2030

  • Report
  • 194 Pages
  • Global
From
United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Image

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • 88 Pages
  • United States
From
Liver Cancer Drugs: Global Strategic Business Report - Product Image

Liver Cancer Drugs: Global Strategic Business Report

  • Report
  • 277 Pages
  • Global
From
Global Liver Metastases Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Immunotherapy), Primary Cancer, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Liver Metastases Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Immunotherapy), Primary Cancer, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 100 Pages
  • Global
From
Global Oncology Drugs Market by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Distribution - Forecast 2024-2030 - Product Image

Global Oncology Drugs Market by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Distribution - Forecast 2024-2030

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.